News | April 08, 2021
Zydus Cadila announces USFDA approval for Ibrutinib capsules
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Integration of various regulatory agencies with a single-window system and putting in place a transparent, stable, predictable and easy to navigate interface.
Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection.
Lupin will provide five lakh LupiSafe hand sanitizers to policemen and frontline workers deployed at strategic locations
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Subscribe To Our Newsletter & Stay Updated
